Navigation Links
Quercegen Pharmaceuticals LLC Obtains FDA GRAS Notified Status for its QU995™ Quercetin with Purity Greater than 99.5%
Date:2/3/2011

e Armed Services Committee, United States House of Representatives, March 13, 2008.

(*RealFX Q-Plus™ was rebranded as Q-Force™ in 2010)

Quercetin has been the subject of over 7,000 research studies and the Company's QU995™ has been used in U.S. Department of Defense funded clinical trials in animals and humans since 2006.

"Quercetin exerts strong anti-oxidative, anti-inflammatory, anti-pathogenic, and immune regulatory effects in vitro and in animal-based studies. Epidemiological data indicates reduced rates of cardiovascular disease and various types of cancer in groups self-selecting diets high in Quercetin. Several recent supplementation studies in athletes have focused on Quercetin's potential influences as a countermeasure to post-exercise inflammation, oxidative stress, and immune dysfunction, in improving endurance performance, and in reducing illness rates following periods of physiological stress."

--David C. Nieman, DrPH, FACSM

Director, Human Performance Lab, North Carolina Research Campus

Professor, Appalachian State University

About Quercegen Pharmaceuticals

Quercegen Pharmaceuticals and its affiliates research, develop, manufacture, and market proprietary plant-derived pharmaceutical ingredients and nutraceutical products in the U.S. and abroad. One of the Company's affiliates, Quercegen Agronegocios, is the world's largest producer of Quercetin and operates a 3,600 hectare farm in northern Brazil. It processes plant materials into crude Rutin and Quercetin for purification at its plant in Sao Luiz and the resulting purified products are shipped around the world for inclusion in pharmaceuticals, dietary supplements and foodstuffs.

Quercegen together with Merck S.A. developed QU995™, the World's Purest Quercetin™, through a patented extraction and purification process. The Company has improved the bioavailability of the flavonoid Quercet
'/>"/>

SOURCE Quercegen Pharmaceuticals LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... 8, 2007--The World Health Organization,has released new ... rising in,Pakistan. , So is this another ... pharmaceutical industry is denying important vaccines to,poor ... to London’s Guardian,newspaper, “parents of 24,000 children ...
... Outlines Development Plans - , ,OTTAWA, Canada – ... company specializing in developing,advanced products related to High ... results of,the Phase I/II Clinical Trial of its ... treatment of dyslipidemia and heart,disease. , ,Results showed, ...
Cached Medicine Technology:Why Is Polio Spreading in Pakistan? 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3
(Date:12/26/2014)... (PRWEB) December 26, 2014 DW-InductionHeating.com (DaWei ... in designing, researching and developing, producing and marketing of ... of the business announces their new series of ... manager of the company, induction brazing refers ... a special filler material and heat. The manager says ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... early stage breast cancer patients who undergo chemotherapy and/or ... eventually develop leukemia as a result of their treatment, ... a review of more than 20,000 breast cancer cases ... the risk for developing treatment-related leukemia, though low, is ... frequency of bone marrow cancers such as leukemia is ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... advisory committee to the U.S. Food and Drug Administration recommended ... used without a prescription. The FDA does not have to ... does. There is no deadline for making a decision. // ... the ability to do both good and harm. Claritin, Allegra ...
... Hypertensive drugs in general have a common side effect- ... plagues people on a widely-used blood pressure medication.// ... treat high blood pressure, heart failure and other cardiac ... inhibitors are troubled by a cough. The side effect ...
... contains polyphenols in the form of flavonoids and its ... properties. Polyphenols protect the cells from damaging// physiological process ... Oxidation produces free radicals these are unstable ... increased amount of them can damage cells resulting in ...
... supplements of a fatty acid found in fish oil halves ... research has found that eating oily fish such as tuna ... caused by a particular type of irregular heartbeat. This study ... a therapy without side effects for heart patients. ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... An Australian psychiatrist has discovered that treating patients with ... Although antipsychotic drugs like risperidone have been shown to ... researchers have suspected for some time that oestrogen can ... version of the disease than men and it usually ...
Cached Medicine News:
... elitewas designed to improve patient compliance. Its ... sample collection options make this fecal occult ... and complete. Diet guidelines are explained in ... which foods and drugs are okay and ...
Inquire...
... The FSH Menopause Predictor Test ... for the detection of Follicle Stimulating ... confirmation of body hormone changes related ... changes of menopause. The FHS ...
... pylori Rapid Test Strip and Device are ... of antibodies to Helicobacter pylori (H. pylori) ... aid in the diagnosis of H. pylori ... and older. They are intended for health ...
Medicine Products: